

GEOVAX LABS, INC.
Condensed Consolidated Statements of Operations Information
(amounts in thousands, except common share information)

	Year Ended December 31,	
	2020	2019
Grant and collaboration revenue	\$ 1,823	\$ 1,176
Operating expenses:		
Research and development	2,444	1,911
General and administrative	2,196	1,637
	4,640	3,548
Loss from operations	(2,817)	(2,372)
Other income (expense), net	(141)	2
Net loss	\$ (2,958)	\$ (2,371)
Net loss per common share	\$ (2.14)	\$ (781.87)
Weighted average shares outstanding	1,383,523	3,032

Condensed Consolidated Balance Sheet Information
(amounts in thousands, except common share information)

	December 31,	
	2020	2019
Assets:		
Cash and cash equivalents	\$ 9,884	\$ 283
Other current assets	351	164
Total current assets	10,235	447
Property and other assets	159	22
Total assets	\$ 10,394	\$ 469
Liabilities and stockholders' equity		
Total liabilities	\$ 825	\$ 2,043
Stockholders' equity (deficiency)	9,569	(1,574)
Total liabilities and stockholders' equity	\$ 10,394	\$ 469
Common Shares Outstanding	3,832,892	14,992